WESTFIELD, N.J., Oct. 11, 2017 /PRNewswire/ -- Relburn-Metabolomics, Inc. announced that the Company will update scientific findings and clinical development plans for its drug candidates in two diseases, nonalcoholic steatohepatitis (NASH) and gout. The presentation by the Relburn Chief Executive, Dr. Raymond P. Warrell, Jr., will occur at the BIO Investor Forum, held at the Westin St. Francis Hotel in San Francisco, on October 17, 2017 at 3:15PM.
In clinical trials of safety and efficacy in more than 350 patients, Relburn investigators observed marked reductions in serum uric acid using a drug prototype, known as RLBN1001. Uric acid is an emerging drug target in multiple diseases, and Relburn has focused on two illnesses, NASH and gout. The prototype drug was used to synthesize more than 140 patented derivatives that have progressed through preclinical studies into clinical leads. These drugs are highly potent bifunctional inhibitors of enzymes that regulate both production and excretion of uric acid -- mechanisms that account for the extraordinary clinical activity of the prototype.
The Company has initiated discussions for a Series A financing that will enable Investigational New Drug (IND) submissions to the Food and Drug Administration for two discrete drug candidates, one each in NASH and gout, along with completion of Phase 1a/1b clinical trials in both illnesses.
About NASH and Gout
Relburn target diseases share a common characteristic: excessive levels of serum uric acid that can induce inflammation that lead to progressive illness, debilitation and organ failure. The Company seeks to develop novel transformational therapy for these illnesses that currently afflict at least 16 million subjects in the U.S./EU and are epidemic in Asia.
All patients with gout have excess uric acid in blood and connective tissues, which can lead to exquisitely painful and destructive arthritis, kidney failure, and possibly accelerated cardiovascular disease. In NASH, about 50% of patients have high uric acid, which can stimulate both uptake of liver fat and triggering of inflammation (i.e., steatohepatitis). Uric acid has been proposed as a treatment target for patients who may benefit from potent, effective reduction of this chemical. Fewer than 25% of gout patients actually respond to standard 1st-line treatment, whereas no drugs have yet been approved for NASH.
Relburn is an emerging life-science company focused on improving health for patients with inflammatory and metabolic diseases. Targeting enzymes that regulate both production and excretion of uric acid, Relburn compounds are markedly more potent than standard monofunctional drugs and have demonstrated exceptional clinical activity. In NASH and gout, effective treatment could relieve both morbidity and mortality from these progressive illnesses. Further information can be accessed at: www.relburn.com.
Relburn company information: firstname.lastname@example.org
Joshua E. Drumm, Ph.D.
SOURCE Relburn-Metabolomics, Inc.